HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing ...
Dentin tubule occlusion was shown to occur at Day 1 and Day 5 during the ADA Forsyth Institute's first-in-human, proof-of-concept trial of Sensi-IP, a novel bioactive glass incorporated in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results